What is HC Wainwright’s Forecast for ENVB Q4 Earnings?

Enveric Biosciences, Inc. (NASDAQ:ENVB) – HC Wainwright issued their Q4 2024 EPS estimates for shares of Enveric Biosciences in a report released on Thursday, March 6th. HC Wainwright analyst V. Bernardino anticipates that the company will post earnings per share of ($0.23) for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Enveric Biosciences’ current full-year earnings is ($31.18) per share. HC Wainwright also issued estimates for Enveric Biosciences’ FY2025 earnings at ($0.86) EPS.

Enveric Biosciences Stock Down 1.2 %

Shares of ENVB stock opened at $1.70 on Monday. Enveric Biosciences has a 12-month low of $1.13 and a 12-month high of $28.05. The company has a market capitalization of $1.15 million, a P/E ratio of -0.04 and a beta of 0.47. The firm has a 50-day moving average price of $3.37 and a 200 day moving average price of $5.36.

Hedge Funds Weigh In On Enveric Biosciences

An institutional investor recently raised its position in Enveric Biosciences stock. AdvisorShares Investments LLC boosted its position in shares of Enveric Biosciences, Inc. (NASDAQ:ENVB) by 63.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 599,854 shares of the company’s stock after purchasing an additional 232,807 shares during the period. AdvisorShares Investments LLC owned about 88.21% of Enveric Biosciences worth $215,000 at the end of the most recent quarter. Institutional investors and hedge funds own 13.82% of the company’s stock.

About Enveric Biosciences

Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.